Galmed Pharmaceuticals Ownership 2024 | Who Owns Galmed Pharmaceuticals Now?
Institutional Ownership
122.57%
Insider Ownership
3.66%
Retail Ownership
-26.23%
Institutional Holders
20.00
Galmed Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WELLS FARGO & COMPANY/MN | - | - | - | -3,050 | -100.00% | - | Jun 30, 2023 |
MORGAN STANLEY | - | - | - | -204,245 | -100.00% | - | Jun 30, 2023 |
BVF INC/IL | - | - | - | -1,347,755 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES & ASSOCIATES | - | - | - | -138,040 | -100.00% | - | Jun 30, 2023 |
BOURGEON CAPITAL MANAGEMENT LLC | - | - | - | -500 | -100.00% | - | Jun 30, 2023 |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | - | - | - | -10 | -100.00% | - | Jun 30, 2023 |
BNP PARIBAS ARBITRAGE, SNC | - | - | - | -13,716 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -27,177 | -100.00% | - | Jun 30, 2023 |
MILLENNIUM MANAGEMENT LLC | - | - | - | -131,628 | -100.00% | - | Jun 30, 2023 |
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | - | - | - | -28,500 | -100.00% | - | Jun 30, 2023 |
CITADEL ADVISORS LLC | - | - | - | -40,844 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. | - | - | - | -27,900 | -100.00% | - | Jun 30, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -31,633 | -100.00% | - | Jun 30, 2023 |
ALLWORTH FINANCIAL LP | - | - | - | -250 | -100.00% | - | Jun 30, 2023 |
JANE STREET GROUP, LLC | - | - | - | -13,189 | -100.00% | - | Jun 30, 2023 |
UBS GROUP AG | - | - | - | -4,307 | -100.00% | - | Jun 30, 2023 |
BELPOINTE ASSET MANAGEMENT LLC | - | - | - | -14,050 | -100.00% | - | Jun 30, 2023 |
TSFG, LLC | - | - | - | -3,000 | -100.00% | - | Jun 30, 2023 |
ZRC WEALTH MANAGEMENT, LLC | - | - | - | -100 | -100.00% | - | Jun 30, 2023 |
Galmed Pharmaceuticals's largest institutional shareholder is WELLS FARGO & COMPANY/MN, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WELLS FARGO & COMPANY/MN | - | - | - | -3,050 | -100.00% | - | Jun 30, 2023 |
MORGAN STANLEY | - | - | - | -204,245 | -100.00% | - | Jun 30, 2023 |
BVF INC/IL | - | - | - | -1,347,755 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES & ASSOCIATES | - | - | - | -138,040 | -100.00% | - | Jun 30, 2023 |
BOURGEON CAPITAL MANAGEMENT LLC | - | - | - | -500 | -100.00% | - | Jun 30, 2023 |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | - | - | - | -10 | -100.00% | - | Jun 30, 2023 |
BNP PARIBAS ARBITRAGE, SNC | - | - | - | -13,716 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -27,177 | -100.00% | - | Jun 30, 2023 |
MILLENNIUM MANAGEMENT LLC | - | - | - | -131,628 | -100.00% | - | Jun 30, 2023 |
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | - | - | - | -28,500 | -100.00% | - | Jun 30, 2023 |
CITADEL ADVISORS LLC | - | - | - | -40,844 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. | - | - | - | -27,900 | -100.00% | - | Jun 30, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -31,633 | -100.00% | - | Jun 30, 2023 |
ALLWORTH FINANCIAL LP | - | - | - | -250 | -100.00% | - | Jun 30, 2023 |
JANE STREET GROUP, LLC | - | - | - | -13,189 | -100.00% | - | Jun 30, 2023 |
UBS GROUP AG | - | - | - | -4,307 | -100.00% | - | Jun 30, 2023 |
BELPOINTE ASSET MANAGEMENT LLC | - | - | - | -14,050 | -100.00% | - | Jun 30, 2023 |
TSFG, LLC | - | - | - | -3,000 | -100.00% | - | Jun 30, 2023 |
ZRC WEALTH MANAGEMENT, LLC | - | - | - | -100 | -100.00% | - | Jun 30, 2023 |
The largest Galmed Pharmaceuticals shareholder by % of total assets is WELLS FARGO & COMPANY/MN. The company owns 0.00 shares of Galmed Pharmaceuticals (GLMD), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | - | - | - | -10 | -100.00% | - | Jun 30, 2023 |
ZRC WEALTH MANAGEMENT, LLC | - | - | - | -100 | -100.00% | - | Jun 30, 2023 |
ALLWORTH FINANCIAL LP | - | - | - | -250 | -100.00% | - | Jun 30, 2023 |
BOURGEON CAPITAL MANAGEMENT LLC | - | - | - | -500 | -100.00% | - | Jun 30, 2023 |
TSFG, LLC | - | - | - | -3,000 | -100.00% | - | Jun 30, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -3,050 | -100.00% | - | Jun 30, 2023 |
UBS GROUP AG | - | - | - | -4,307 | -100.00% | - | Jun 30, 2023 |
JANE STREET GROUP, LLC | - | - | - | -13,189 | -100.00% | - | Jun 30, 2023 |
BNP PARIBAS ARBITRAGE, SNC | - | - | - | -13,716 | -100.00% | - | Jun 30, 2023 |
BELPOINTE ASSET MANAGEMENT LLC | - | - | - | -14,050 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -27,177 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. | - | - | - | -27,900 | -100.00% | - | Jun 30, 2023 |
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | - | - | - | -28,500 | -100.00% | - | Jun 30, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -31,633 | -100.00% | - | Jun 30, 2023 |
CITADEL ADVISORS LLC | - | - | - | -40,844 | -100.00% | - | Jun 30, 2023 |
MILLENNIUM MANAGEMENT LLC | - | - | - | -131,628 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES & ASSOCIATES | - | - | - | -138,040 | -100.00% | - | Jun 30, 2023 |
MORGAN STANLEY | - | - | - | -204,245 | -100.00% | - | Jun 30, 2023 |
BVF INC/IL | - | - | - | -1,347,755 | -100.00% | - | Jun 30, 2023 |
As of Jun 30 2023, Galmed Pharmaceuticals's largest institutional buyer is NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO. The company purchased -10.00 stocks of GLMD, valued at -.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BVF INC/IL | - | - | - | -1,347,755 | -100.00% | - | Jun 30, 2023 |
MORGAN STANLEY | - | - | - | -204,245 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES & ASSOCIATES | - | - | - | -138,040 | -100.00% | - | Jun 30, 2023 |
MILLENNIUM MANAGEMENT LLC | - | - | - | -131,628 | -100.00% | - | Jun 30, 2023 |
CITADEL ADVISORS LLC | - | - | - | -40,844 | -100.00% | - | Jun 30, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -31,633 | -100.00% | - | Jun 30, 2023 |
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | - | - | - | -28,500 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. | - | - | - | -27,900 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -27,177 | -100.00% | - | Jun 30, 2023 |
BELPOINTE ASSET MANAGEMENT LLC | - | - | - | -14,050 | -100.00% | - | Jun 30, 2023 |
BNP PARIBAS ARBITRAGE, SNC | - | - | - | -13,716 | -100.00% | - | Jun 30, 2023 |
JANE STREET GROUP, LLC | - | - | - | -13,189 | -100.00% | - | Jun 30, 2023 |
UBS GROUP AG | - | - | - | -4,307 | -100.00% | - | Jun 30, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -3,050 | -100.00% | - | Jun 30, 2023 |
TSFG, LLC | - | - | - | -3,000 | -100.00% | - | Jun 30, 2023 |
BOURGEON CAPITAL MANAGEMENT LLC | - | - | - | -500 | -100.00% | - | Jun 30, 2023 |
ALLWORTH FINANCIAL LP | - | - | - | -250 | -100.00% | - | Jun 30, 2023 |
ZRC WEALTH MANAGEMENT, LLC | - | - | - | -100 | -100.00% | - | Jun 30, 2023 |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | - | - | - | -10 | -100.00% | - | Jun 30, 2023 |
As of Jun 30 2023, Galmed Pharmaceuticals's biggest institutional seller is BVF INC/IL. The company sold -1.35M shares of GLMD, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BVF INC/IL | - | - | - | -1,347,755 | -100.00% | - | Jun 30, 2023 |
MORGAN STANLEY | - | - | - | -204,245 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES & ASSOCIATES | - | - | - | -138,040 | -100.00% | - | Jun 30, 2023 |
MILLENNIUM MANAGEMENT LLC | - | - | - | -131,628 | -100.00% | - | Jun 30, 2023 |
CITADEL ADVISORS LLC | - | - | - | -40,844 | -100.00% | - | Jun 30, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -31,633 | -100.00% | - | Jun 30, 2023 |
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | - | - | - | -28,500 | -100.00% | - | Jun 30, 2023 |
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. | - | - | - | -27,900 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -27,177 | -100.00% | - | Jun 30, 2023 |
BELPOINTE ASSET MANAGEMENT LLC | - | - | - | -14,050 | -100.00% | - | Jun 30, 2023 |
BNP PARIBAS ARBITRAGE, SNC | - | - | - | -13,716 | -100.00% | - | Jun 30, 2023 |
JANE STREET GROUP, LLC | - | - | - | -13,189 | -100.00% | - | Jun 30, 2023 |
UBS GROUP AG | - | - | - | -4,307 | -100.00% | - | Jun 30, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -3,050 | -100.00% | - | Jun 30, 2023 |
TSFG, LLC | - | - | - | -3,000 | -100.00% | - | Jun 30, 2023 |
BOURGEON CAPITAL MANAGEMENT LLC | - | - | - | -500 | -100.00% | - | Jun 30, 2023 |
ALLWORTH FINANCIAL LP | - | - | - | -250 | -100.00% | - | Jun 30, 2023 |
ZRC WEALTH MANAGEMENT, LLC | - | - | - | -100 | -100.00% | - | Jun 30, 2023 |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | - | - | - | -10 | -100.00% | - | Jun 30, 2023 |
Galmed Pharmaceuticals's largest sold out institutional shareholder by shares sold is BVF INC/IL, sold -1.35M shares, valued at -, as of undefined.
Galmed Pharmaceuticals Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
ETF Managers Trust | 0.01% | 72,640 | - | - | Dec 31, 2023 |
ETF Series Solutions | 0.00% | 24,657 | - | - | Jan 31, 2024 |
NORTHERN FUNDS | 0.00% | 209 | - | - | Mar 28, 2024 |
Galmed Pharmaceuticals's largest mutual fund holder by % of total assets is "ETF Managers Trust", owning 72.64K shares, compromising 0.01% of its total assets.
Galmed Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Mar, 23 | 20 | 5.26% |
31 Dec, 22 | 19 | -13.64% |
30 Sep, 22 | 22 | 4.76% |
30 Jun, 22 | 21 | -12.50% |
31 Mar, 22 | 24 | -4.00% |
31 Dec, 21 | 25 | -3.85% |
30 Sep, 21 | 26 | - |
30 Jun, 21 | 26 | -10.34% |
31 Mar, 21 | 29 | 38.10% |
31 Dec, 20 | 21 | -8.70% |
30 Sep, 20 | 23 | -4.17% |
30 Jun, 20 | 24 | -22.58% |
31 Mar, 20 | 31 | - |
31 Dec, 19 | 31 | 6.90% |
30 Sep, 19 | 29 | -12.12% |
30 Jun, 19 | 33 | -5.71% |
31 Mar, 19 | 35 | -20.45% |
31 Dec, 18 | 44 | 12.82% |
30 Sep, 18 | 39 | -11.36% |
30 Jun, 18 | 44 | 120.00% |
31 Mar, 18 | 20 | 5.26% |
31 Dec, 17 | 19 | 72.73% |
30 Sep, 17 | 11 | 10.00% |
30 Jun, 17 | 10 | 25.00% |
31 Mar, 17 | 8 | -38.46% |
31 Dec, 16 | 13 | -23.53% |
30 Sep, 16 | 17 | -5.56% |
30 Jun, 16 | 18 | - |
31 Mar, 16 | 18 | -10.00% |
31 Dec, 15 | 20 | -4.76% |
30 Sep, 15 | 21 | -4.55% |
30 Jun, 15 | 22 | - |
31 Mar, 15 | 22 | 37.50% |
31 Dec, 14 | 16 | -15.79% |
30 Sep, 14 | 19 | -9.52% |
30 Jun, 14 | 21 | 5.00% |
31 Mar, 14 | 20 | - |
As of 31 Mar 23, 20 institutions are holding Galmed Pharmaceuticals's shares, representing an increase of 5.26% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Mar, 23 | 2,059,431 | -14.66% |
31 Dec, 22 | 2,413,092 | -6.53% |
30 Sep, 22 | 2,581,787 | 2.46% |
30 Jun, 22 | 2,519,684 | -10.32% |
31 Mar, 22 | 2,809,617 | -27.45% |
31 Dec, 21 | 3,872,865 | -8.40% |
30 Sep, 21 | 4,227,922 | -11.95% |
30 Jun, 21 | 4,801,892 | -15.00% |
31 Mar, 21 | 5,649,378 | -9.81% |
31 Dec, 20 | 6,264,175 | -5.89% |
30 Sep, 20 | 6,656,415 | -10.28% |
30 Jun, 20 | 7,419,165 | 3.72% |
31 Mar, 20 | 7,152,866 | 21.51% |
31 Dec, 19 | 5,886,801 | -6.58% |
30 Sep, 19 | 6,301,684 | -18.52% |
30 Jun, 19 | 7,733,770 | 3.44% |
31 Mar, 19 | 7,476,900 | -2.22% |
31 Dec, 18 | 7,646,947 | 0.45% |
30 Sep, 18 | 7,612,638 | -14.32% |
30 Jun, 18 | 8,885,013 | 233.19% |
31 Mar, 18 | 2,666,611 | -2.30% |
31 Dec, 17 | 2,729,302 | 117.61% |
30 Sep, 17 | 1,254,222 | 19.32% |
30 Jun, 17 | 1,051,132 | 14.34% |
31 Mar, 17 | 919,326 | 2.76% |
31 Dec, 16 | 894,623 | 26.67% |
30 Sep, 16 | 706,240 | 28.37% |
30 Jun, 16 | 550,148 | -23.83% |
31 Mar, 16 | 722,308 | -7.27% |
31 Dec, 15 | 778,961 | -84.69% |
30 Sep, 15 | 5,087,073 | 512.39% |
30 Jun, 15 | 830,694 | -12.42% |
31 Mar, 15 | 948,493 | 1.97% |
31 Dec, 14 | 930,177 | -20.04% |
30 Sep, 14 | 1,163,288 | -36.08% |
30 Jun, 14 | 1,820,052 | 8.40% |
31 Mar, 14 | 1,678,980 | - |
Galmed Pharmaceuticals (GLMD) has 2.06M shares outstanding as of 31 Mar 23, down -14.66% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Mar, 23 | 122.57% | 0.59% |
31 Dec, 22 | 143.62% | 0.61% |
30 Sep, 22 | 153.66% | 0.68% |
30 Jun, 22 | 149.96% | 0.54% |
31 Mar, 22 | 167.22% | 0.31% |
31 Dec, 21 | 230.50% | 0.36% |
30 Sep, 21 | 251.63% | 0.31% |
30 Jun, 21 | 285.79% | 0.25% |
31 Mar, 21 | 336.23% | 0.24% |
31 Dec, 20 | 372.82% | 0.24% |
30 Sep, 20 | 396.16% | 0.20% |
30 Jun, 20 | 441.56% | 0.24% |
31 Mar, 20 | 425.71% | 0.35% |
31 Dec, 19 | 350.36% | 0.25% |
30 Sep, 19 | 375.05% | 0.18% |
30 Jun, 19 | 460.28% | 0.23% |
31 Mar, 19 | 444.99% | 0.21% |
31 Dec, 18 | 455.11% | 0.22% |
30 Sep, 18 | 453.07% | 0.16% |
30 Jun, 18 | 528.80% | 2.10% |
31 Mar, 18 | 158.71% | 0.60% |
31 Dec, 17 | 162.44% | 2.92% |
30 Sep, 17 | 74.65% | 1.91% |
30 Jun, 17 | 62.56% | 2.09% |
31 Mar, 17 | 54.71% | 1.93% |
31 Dec, 16 | 53.24% | 3.01% |
30 Sep, 16 | 42.03% | 3.92% |
30 Jun, 16 | 32.74% | 1.77% |
31 Mar, 16 | 42.99% | 2.00% |
31 Dec, 15 | 46.36% | 0.05% |
30 Sep, 15 | 302.76% | 12.39% |
30 Jun, 15 | 49.44% | 1.55% |
31 Mar, 15 | 56.45% | 1.84% |
31 Dec, 14 | 55.36% | 1.15% |
30 Sep, 14 | 69.23% | 0.59% |
30 Jun, 14 | 108.32% | 1.08% |
31 Mar, 14 | 99.93% | - |
As of 31 Mar 23, Galmed Pharmaceuticals is held by 122.57% institutional shareholders, representing a 0.59% growth compared to 31 Dec 22.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Mar, 23 | 7 | 40.00% |
31 Dec, 22 | 5 | -37.50% |
30 Sep, 22 | 8 | -20.00% |
30 Jun, 22 | 10 | 66.67% |
31 Mar, 22 | 6 | -25.00% |
31 Dec, 21 | 8 | -11.11% |
30 Sep, 21 | 9 | 80.00% |
30 Jun, 21 | 5 | -64.29% |
31 Mar, 21 | 14 | 40.00% |
31 Dec, 20 | 10 | 11.11% |
30 Sep, 20 | 9 | -10.00% |
30 Jun, 20 | 10 | -33.33% |
31 Mar, 20 | 15 | -6.25% |
31 Dec, 19 | 16 | 33.33% |
30 Sep, 19 | 12 | -14.29% |
30 Jun, 19 | 14 | 7.69% |
31 Mar, 19 | 13 | -38.10% |
31 Dec, 18 | 21 | - |
30 Sep, 18 | 21 | -41.67% |
30 Jun, 18 | 36 | 227.27% |
31 Mar, 18 | 11 | -26.67% |
31 Dec, 17 | 15 | 114.29% |
30 Sep, 17 | 7 | 40.00% |
30 Jun, 17 | 5 | 66.67% |
31 Mar, 17 | 3 | -50.00% |
31 Dec, 16 | 6 | -33.33% |
30 Sep, 16 | 9 | 28.57% |
30 Jun, 16 | 7 | 16.67% |
31 Mar, 16 | 6 | - |
31 Dec, 15 | 6 | -45.45% |
30 Sep, 15 | 11 | 22.22% |
30 Jun, 15 | 9 | -25.00% |
31 Mar, 15 | 12 | 20.00% |
31 Dec, 14 | 10 | - |
30 Sep, 14 | 10 | - |
30 Jun, 14 | 10 | -50.00% |
31 Mar, 14 | 20 | - |
7 institutional shareholders have increased their position in GLMD stock as of 31 Mar 23 compared to 5 in the previous quarter (a 40.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Mar, 23 | 4 | -63.64% |
31 Dec, 22 | 11 | 57.14% |
30 Sep, 22 | 7 | 133.33% |
30 Jun, 22 | 3 | -40.00% |
31 Mar, 22 | 5 | -16.67% |
31 Dec, 21 | 6 | 20.00% |
30 Sep, 21 | 5 | -44.44% |
30 Jun, 21 | 9 | 125.00% |
31 Mar, 21 | 4 | -20.00% |
31 Dec, 20 | 5 | 25.00% |
30 Sep, 20 | 4 | 33.33% |
30 Jun, 20 | 3 | -50.00% |
31 Mar, 20 | 6 | - |
31 Dec, 19 | 6 | - |
30 Sep, 19 | 6 | -40.00% |
30 Jun, 19 | 10 | -9.09% |
31 Mar, 19 | 11 | - |
31 Dec, 18 | 11 | 57.14% |
30 Sep, 18 | 7 | 133.33% |
30 Jun, 18 | 3 | -25.00% |
31 Mar, 18 | 4 | - |
31 Dec, 17 | - | -100.00% |
30 Sep, 17 | 1 | - |
30 Jun, 17 | - | - |
31 Mar, 17 | - | -100.00% |
31 Dec, 16 | 2 | 100.00% |
30 Sep, 16 | 1 | -50.00% |
30 Jun, 16 | 2 | -50.00% |
31 Mar, 16 | 4 | -20.00% |
31 Dec, 15 | 5 | 400.00% |
30 Sep, 15 | 1 | -83.33% |
30 Jun, 15 | 6 | 50.00% |
31 Mar, 15 | 4 | 300.00% |
31 Dec, 14 | 1 | -80.00% |
30 Sep, 14 | 5 | 66.67% |
30 Jun, 14 | 3 | - |
31 Mar, 14 | - | - |
4 institutional shareholders have reduced their position in GLMD stock as of 31 Mar 23 compared to 11 in the previous quarter (a -63.64% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar, 23 | 20 | 5.26% | 2,059,431 | -14.66% | 122.57% | 0.59% | 7 | 40.00% | 4 | -63.64% |
31 Dec, 22 | 19 | -13.64% | 2,413,092 | -6.53% | 143.62% | 0.61% | 5 | -37.50% | 11 | 57.14% |
30 Sep, 22 | 22 | 4.76% | 2,581,787 | 2.46% | 153.66% | 0.68% | 8 | -20.00% | 7 | 133.33% |
30 Jun, 22 | 21 | -12.50% | 2,519,684 | -10.32% | 149.96% | 0.54% | 10 | 66.67% | 3 | -40.00% |
31 Mar, 22 | 24 | -4.00% | 2,809,617 | -27.45% | 167.22% | 0.31% | 6 | -25.00% | 5 | -16.67% |
31 Dec, 21 | 25 | -3.85% | 3,872,865 | -8.40% | 230.50% | 0.36% | 8 | -11.11% | 6 | 20.00% |
30 Sep, 21 | 26 | - | 4,227,922 | -11.95% | 251.63% | 0.31% | 9 | 80.00% | 5 | -44.44% |
30 Jun, 21 | 26 | -10.34% | 4,801,892 | -15.00% | 285.79% | 0.25% | 5 | -64.29% | 9 | 125.00% |
31 Mar, 21 | 29 | 38.10% | 5,649,378 | -9.81% | 336.23% | 0.24% | 14 | 40.00% | 4 | -20.00% |
31 Dec, 20 | 21 | -8.70% | 6,264,175 | -5.89% | 372.82% | 0.24% | 10 | 11.11% | 5 | 25.00% |
30 Sep, 20 | 23 | -4.17% | 6,656,415 | -10.28% | 396.16% | 0.20% | 9 | -10.00% | 4 | 33.33% |
30 Jun, 20 | 24 | -22.58% | 7,419,165 | 3.72% | 441.56% | 0.24% | 10 | -33.33% | 3 | -50.00% |
31 Mar, 20 | 31 | - | 7,152,866 | 21.51% | 425.71% | 0.35% | 15 | -6.25% | 6 | - |
31 Dec, 19 | 31 | 6.90% | 5,886,801 | -6.58% | 350.36% | 0.25% | 16 | 33.33% | 6 | - |
30 Sep, 19 | 29 | -12.12% | 6,301,684 | -18.52% | 375.05% | 0.18% | 12 | -14.29% | 6 | -40.00% |
30 Jun, 19 | 33 | -5.71% | 7,733,770 | 3.44% | 460.28% | 0.23% | 14 | 7.69% | 10 | -9.09% |
31 Mar, 19 | 35 | -20.45% | 7,476,900 | -2.22% | 444.99% | 0.21% | 13 | -38.10% | 11 | - |
31 Dec, 18 | 44 | 12.82% | 7,646,947 | 0.45% | 455.11% | 0.22% | 21 | - | 11 | 57.14% |
30 Sep, 18 | 39 | -11.36% | 7,612,638 | -14.32% | 453.07% | 0.16% | 21 | -41.67% | 7 | 133.33% |
30 Jun, 18 | 44 | 120.00% | 8,885,013 | 233.19% | 528.80% | 2.10% | 36 | 227.27% | 3 | -25.00% |
31 Mar, 18 | 20 | 5.26% | 2,666,611 | -2.30% | 158.71% | 0.60% | 11 | -26.67% | 4 | - |
31 Dec, 17 | 19 | 72.73% | 2,729,302 | 117.61% | 162.44% | 2.92% | 15 | 114.29% | - | -100.00% |
30 Sep, 17 | 11 | 10.00% | 1,254,222 | 19.32% | 74.65% | 1.91% | 7 | 40.00% | 1 | - |
30 Jun, 17 | 10 | 25.00% | 1,051,132 | 14.34% | 62.56% | 2.09% | 5 | 66.67% | - | - |
31 Mar, 17 | 8 | -38.46% | 919,326 | 2.76% | 54.71% | 1.93% | 3 | -50.00% | - | -100.00% |
31 Dec, 16 | 13 | -23.53% | 894,623 | 26.67% | 53.24% | 3.01% | 6 | -33.33% | 2 | 100.00% |
30 Sep, 16 | 17 | -5.56% | 706,240 | 28.37% | 42.03% | 3.92% | 9 | 28.57% | 1 | -50.00% |
30 Jun, 16 | 18 | - | 550,148 | -23.83% | 32.74% | 1.77% | 7 | 16.67% | 2 | -50.00% |
31 Mar, 16 | 18 | -10.00% | 722,308 | -7.27% | 42.99% | 2.00% | 6 | - | 4 | -20.00% |
31 Dec, 15 | 20 | -4.76% | 778,961 | -84.69% | 46.36% | 0.05% | 6 | -45.45% | 5 | 400.00% |
30 Sep, 15 | 21 | -4.55% | 5,087,073 | 512.39% | 302.76% | 12.39% | 11 | 22.22% | 1 | -83.33% |
30 Jun, 15 | 22 | - | 830,694 | -12.42% | 49.44% | 1.55% | 9 | -25.00% | 6 | 50.00% |
31 Mar, 15 | 22 | 37.50% | 948,493 | 1.97% | 56.45% | 1.84% | 12 | 20.00% | 4 | 300.00% |
31 Dec, 14 | 16 | -15.79% | 930,177 | -20.04% | 55.36% | 1.15% | 10 | - | 1 | -80.00% |
30 Sep, 14 | 19 | -9.52% | 1,163,288 | -36.08% | 69.23% | 0.59% | 10 | - | 5 | 66.67% |
30 Jun, 14 | 21 | 5.00% | 1,820,052 | 8.40% | 108.32% | 1.08% | 10 | -50.00% | 3 | - |
31 Mar, 14 | 20 | - | 1,678,980 | - | 99.93% | - | 20 | - | - | - |
Galmed Pharmaceuticals Peer Ownership
Ticker | Company |
---|---|
AKBA | Akebia Therapeutics, Inc. |
ACHL | Achilles Therapeutics plc |
MREO | Mereo BioPharma Group plc |
ABEO | Abeona Therapeutics Inc. |
PDSB | PDS Biotechnology Corporation |
ADAP | Adaptimmune Therapeutics plc |
FBIO | Fortress Biotech, Inc. |
APTO | Aptose Biosciences Inc. |
ADVM | Adverum Biotechnologies, Inc. |
AFMD | Affimed N.V. |
KOD | Kodiak Sciences Inc. |
MBIO | Mustang Bio, Inc. |
LPTX | Leap Therapeutics, Inc. |
PIRS | Pieris Pharmaceuticals, Inc. |
GLMD Ownership FAQ
Who Owns Galmed Pharmaceuticals?
Galmed Pharmaceuticals is owned by institutional shareholders (122.57%), insiders (3.66%), and public (-26.23%). The largest institutional shareholder of Galmed Pharmaceuticals is WELLS FARGO & COMPANY/MN (0% of total shares) and the top mutual fund owner is ETF Managers Trust (0.01% of total shares).
Who are the major institutional shareholders of Galmed Pharmaceuticals?
Galmed Pharmaceuticals's major institutional shareholders are WELLS FARGO & COMPANY/MN, MORGAN STANLEY, BVF INC/IL, RAYMOND JAMES & ASSOCIATES, and BOURGEON CAPITAL MANAGEMENT LLC. The top five shareholders own together 0% of the company's share outstanding.
How many Galmed Pharmaceuticals shareholders are there?
As of Mar 2023, there are 20 institutional shareholders of Galmed Pharmaceuticals.
What percentage of Galmed Pharmaceuticals is owned by WELLS FARGO & COMPANY/MN?
WELLS FARGO & COMPANY/MN owns 0 shares of Galmed Pharmaceuticals, representing 0% of the company's total shares outstanding, valued at $0 (as of Jun 2023).
What percentage of Galmed Pharmaceuticals is owned by MORGAN STANLEY?
As of Jun 2023, MORGAN STANLEY holds 0 shares of Galmed Pharmaceuticals (GLMD), compromising 0% of the company, valued at $0.
What percentage of Galmed Pharmaceuticals is owned by BVF INC/IL?
BVF INC/IL is the third largest holder of Galmed Pharmaceuticals. The company owns 0 of the company's shares outstanding (worth $0).